AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s maturation strategy remains centered connected processing the marketplace for peripheral nervus repair, portion caller reimbursement wins are expected to beryllium affirmative but person not yet been quantified.

Speaking during a institution event, Dale said helium was drawn to AxoGen due to the fact that peripheral nervus relation represents a “credible wellness condition” with a ample underserved diligent colonisation and due to the fact that the company’s Avance level offers what helium described arsenic a differentiated solution comparative to existing standards of care.

→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?

“It’s a solution that based upon payment versus hazard arsenic compared to existing options, is genuinely superior,” Dale said.

Dale said AxoGen has gone done a accepted strategical readying process involving employees, the board, customers and investors. He emphasized that the institution is operating from a azygous program that has been discussed crossed those stakeholder groups.

Reimbursement Wins Seen arsenic Positive, but Timing Remains Unclear

→ MP Materials Is Quietly Building a Rare Earth Powerhouse

Asked astir precocious announced reimbursement gains and their effect connected gross for the remainder of 2026 and beyond, Dale said the institution is inactive moving to recognize the magnitude and timing of the benefit.

“We cognize it’s each gonna beryllium good,” Dale said, portion adding that the institution has not yet quantified the impact.

→ MercadoLibre Boldly Invests successful Growth: Discount Deepens

He said the process does not enactment similar a “light switch.” After a favorable sum decision, providers indispensable beryllium informed, and past hospitals oregon different healthcare providers whitethorn request to negociate contracts with payers based connected the caller sum policy.

Dale besides said Aetna is the past important payer that has not yet made a decision. He said AxoGen has made ceremonial submissions and requests for valuation nether payer-specific reappraisal processes. Based connected Aetna’s schedule, Dale said the institution hopes to perceive thing by the extremity of June, though helium noted determination is nary warrant oregon work for Aetna to respond.